The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

The Food and Drug Administration (FDA)-National Institute of Mental Health (NIMH)-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) clinical trial guidelines for cognitive-enhancing drugs in schizophrenia and the MATRICS Consensus Cognitive Battery (MCCB) were designed to facilitate novel compound development in the treatment of cognitive impairments. Several studies have recently utilized the FDA-NIMH-MATRICS guidelines and MCCB and allow an evaluation of the feasibility of guideline implementation and MCCB performance. In light of the study results, we would recommend the following inclusion criteria revisions-(1) clinical status and symptom inclusion criteria: maximum allowed score for hallucinations and delusions should be increased from moderate to moderately severe and the negative symptom criterion should be dropped in phase 2 studies; (2) antipsychotic medication inclusion criteria: first-generation antipsychotics should be allowed, but only in the context of no concomitant anticholinergic agents and minimal extrapyramidal symptoms, and antipsychotic polypharmacy should be allowed in the absence of pertinent pharmacokinetic or pharmacodynamic considerations; and (3) people who use illicit substances should not be allowed in phase 1B or 2A proof-of-concept studies but may be included in phase 2B and 3 studies in which proof of effectiveness and generalizability of results become more important goals. These revisions are recommended to enhance recruitment while maintaining sufficient methodological rigor to ensure the validity of study results. The MCCB has been shown to have excellent psychometric characteristics, including reliability for multisite clinical trials, clinical relevance for real-world functioning, and possible sensitivity to behavioral treatment, and should continue to serve as the standard outcome measure for cognitive enhancement studies in schizophrenia.

[1]  Michael F. Green,et al.  Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS , 2004, Schizophrenia Research.

[2]  J. Gold,et al.  Initial phase 2 trial of a nicotinic agonist in schizophrenia. , 2008, The American journal of psychiatry.

[3]  R. Bilder,et al.  Clinical global impression of cognition in schizophrenia (CGI-CogS): Reliability and validity of a co-primary measure of cognition , 2008, Schizophrenia Research.

[4]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[5]  Alexander L. Miller,et al.  Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. , 2006, Psychiatric services.

[6]  Michael F. Green,et al.  The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone , 2002, Biological Psychiatry.

[7]  J. Lieberman,et al.  Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia , 2009, Neuropsychopharmacology.

[8]  T L Patterson,et al.  UCSD Performance-Based Skills Assessment , 2016 .

[9]  L. Hranov,et al.  Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.

[10]  N. Andreasen,et al.  Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. , 2005, The American journal of psychiatry.

[11]  J. Levine,et al.  Antipsychotic medication coprescribing in a large state hospital system , 2003, Pharmacoepidemiology and drug safety.

[12]  Todd Lencz,et al.  Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? , 2007, Archives of general psychiatry.

[13]  Philip D. Harvey,et al.  The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. , 2006, The American journal of psychiatry.

[14]  Michael F. Green,et al.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria , 2004, Biological Psychiatry.

[15]  Robert L Levin,et al.  Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. , 2006, Schizophrenia bulletin.

[16]  Michael F. Green,et al.  Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. , 2008, The American journal of psychiatry.

[17]  Michael F. Green,et al.  A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. , 2005, Schizophrenia bulletin.

[18]  Michael F. Green,et al.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. , 2008, The American journal of psychiatry.

[19]  James M Gold,et al.  Galantamine for the treatment of cognitive impairments in people with schizophrenia. , 2008, The American journal of psychiatry.

[20]  B. Martin,et al.  Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. , 2004, The Journal of clinical psychiatry.

[21]  Alexander L. Miller,et al.  Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial , 2006 .

[22]  John S. Brekke,et al.  Direct assessment of functional abilities: relevance to persons with schizophrenia , 2004, Schizophrenia Research.

[23]  M. Valenstein,et al.  Long-term combination antipsychotic treatment in VA patients with schizophrenia , 2006, Schizophrenia Research.

[24]  Philip D. Harvey,et al.  Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. , 2005, The American journal of psychiatry.

[25]  A. Cohen,et al.  Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. , 2007, Schizophrenia bulletin.

[26]  J. Lieberman,et al.  Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. , 2004, The American journal of psychiatry.

[27]  J. Lieberman,et al.  Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.

[28]  Sophia Vinogradov,et al.  The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. , 2009, The American journal of psychiatry.

[29]  Michael F. Green,et al.  The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. , 2008, The American journal of psychiatry.

[30]  Sophia Vinogradov,et al.  Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. , 2009, The American journal of psychiatry.

[31]  S. Marder,et al.  New paradigms for treatment development. , 2007, Schizophrenia bulletin.

[32]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[33]  R. Kahn,et al.  Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). , 2009, The American journal of psychiatry.

[34]  B. Mausbach,et al.  Development of a brief scale of everyday functioning in persons with serious mental illness. , 2006, Schizophrenia bulletin.

[35]  K. Mueser,et al.  Evaluation of social problem solving in schizophrenia. , 1994, Journal of abnormal psychology.

[36]  Aaron L Mishara,et al.  A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book , 2004, Biological Psychiatry.

[37]  R. Buchanan,et al.  A separate disease within the syndrome of schizophrenia. , 2001, Archives of general psychiatry.

[38]  Alexander L. Miller,et al.  The reliability and validity of the Test of Adaptive Behavior in Schizophrenia (TABS) , 2007, Psychiatry Research.